<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837198</url>
  </required_header>
  <id_info>
    <org_study_id>FYU-981-008</org_study_id>
    <nct_id>NCT02837198</nct_id>
  </id_info>
  <brief_title>Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)</brief_title>
  <official_title>Seven-day Repeated Dose Clinical Pharmacological Study of FYU-981 Administered to Hyperuricemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuji Yakuhin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuji Yakuhin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the pharmacodynamics, pharmacokinetics and safety of 7-day-repeated doses of
      FYU-981 administered orally to male hyperuricemic patients with uric acid-overproduction or
      uric acid-underexcretion type.

      In addition, to investigate the additive effects of the combination of FYU-981 and
      topiroxostat administered orally to male hyperuricemic patients with uric acid-overproduction
      type.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics (Amount of uric acid excreted in urine)</measure>
    <time_frame>1-, 2-, 3-, 4-, 5-, 6-,7-,8- and 9-day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (Renal clearance of uric acid)</measure>
    <time_frame>1-, 4- and 7-day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (Fractional uric acid excretion)</measure>
    <time_frame>4- and 7-day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (Maximum delta effective uric acid concentration)</measure>
    <time_frame>1-, 2-, 3-, 4-, 5-, 6- and 7-day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (Delta area under the serum uric acid concentration-time curve)</measure>
    <time_frame>1-, 4- and 7-day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax: Maximum plasma concentration)</measure>
    <time_frame>1-, and 7-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmin: Minimum plasma concentration)</measure>
    <time_frame>1-, 2-, 3-, 4-, 5-, 6- and 7-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tmax: Time to reach the peak plasma concentration)</measure>
    <time_frame>1-, and 7-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (T1/2: Elimination half-life of plasma concentration)</measure>
    <time_frame>1-, and 7-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC: Area under the plasma concentration-time curve)</measure>
    <time_frame>1-, and 7-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (kel: Elimination rate constant)</measure>
    <time_frame>1-, and 7-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Vd/F: Distribution volume / Fraction of dose absorbed)</measure>
    <time_frame>1-, and 7-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (CLtot/F: Total clearance / Fraction of dose absorbed)</measure>
    <time_frame>1-, and 7-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (MRT: Mean residence time)</measure>
    <time_frame>1-, and 7-day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Uric acid-overproduction Type</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FYU-981</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uric acid- underexcretion Type</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FYU-981</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uric acid-overproduction Type (combination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FYU-981 , Topiroxostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FYU-981</intervention_name>
    <arm_group_label>Uric acid-overproduction Type</arm_group_label>
    <arm_group_label>Uric acid- underexcretion Type</arm_group_label>
    <arm_group_label>Uric acid-overproduction Type (combination)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiroxostat</intervention_name>
    <arm_group_label>Uric acid-overproduction Type (combination)</arm_group_label>
    <other_name>FYX-051</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese adult subjects

          -  Serum urate level: &gt;= 7.0mg/dL in patients

          -  Disease Type: Uric acid-overproduction Type or Uric acid-underexcretion Type

        Exclusion Criteria:

          -  Gouty arthritis within a year before start of study treatment

          -  Mixed type in the classification of hyperuricemia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

